Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Sep 30, 2025 | (FY)Nov 30, 2024 | (Q2)May 31, 2024 | (Q1)Feb 29, 2024 | (FY)Nov 30, 2023 | (Q4)Nov 30, 2023 | (Q3)Aug 31, 2023 | (Q2)May 31, 2023 | (Q1)Feb 28, 2023 | (FY)Nov 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -14.24%7.01B | 10.29%8.17B | -3.38%2.2B | 96.50%1.57B | 7.55%7.41B | 2.39B | 69.14%1.94B | 6.65%2.28B | -36.44%799M | 17.73%6.89B |
| Cost of revenue | -17.79%4.55B | -0.31%5.54B | -16.77%1.42B | 52.67%1.06B | 1.93%5.55B | 1.67B | 58.06%1.48B | 2.77%1.71B | -37.06%693M | 17.64%5.45B |
| Gross profit | -6.72%2.46B | 41.96%2.63B | 36.60%780M | 383.02%512M | 28.93%1.85B | 717M | 119.05%460M | 19.96%571M | -31.61%106M | 18.06%1.44B |
| Operating expense | 9.96%1.59B | 38.77%1.45B | 25.33%287M | 0.83%243M | 10.03%1.04B | 325M | 6.01%247M | -7.29%229M | 10.05%241M | 11.41%947M |
| Staff costs | ---- | ---- | ---- | ---- | ---- | ---- | -2.61%112M | ---- | ---- | 5.80%529M |
| Research and development costs | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -46.67%8M |
| Depreciation and amortization | ---- | ---- | ---- | ---- | ---- | ---- | 0.00%4M | ---- | ---- | 5.26%20M |
| -Depreciation | ---- | ---- | ---- | ---- | ---- | ---- | 0.00%4M | ---- | ---- | 5.26%20M |
| Other operating expenses | ---- | ---- | ---- | ---- | ---- | ---- | 14.91%131M | ---- | ---- | 23.42%390M |
| Operating profit | -27.07%865M | 46.06%1.19B | 44.15%493M | 299.26%269M | 65.38%812M | 392M | 1,026.09%213M | 49.34%342M | -110.94%-135M | 33.42%491M |
| Net non-operating interest income (expenses) | 80.00%9M | 225.00%5M | 200.00%1M | 0 | 20.00%-4M | -1M | 50.00%-1M | 0.00%-1M | 0.00%-1M | 16.67%-5M |
| Non-operating interest income | 25.00%10M | --8M | --2M | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Non-operating interest expense | -66.67%1M | -25.00%3M | 0.00%1M | --0 | -20.00%4M | --1M | -50.00%1M | 0.00%1M | 0.00%1M | -16.67%5M |
| Net investment income | 600.00%7M | -87.50%1M | 0.00%1M | 0.00%3M | 14.29%8M | -2M | 100.00%6M | -50.00%1M | 50.00%3M | 0.00%7M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 6,680.00%339M | 66.67%5M | 3M | 0 | 0 | |||||
| Income from associates and other participating interests | -10.71%25M | -36.36%28M | -2M | 6.06%35M | 144.44%44M | 5M | 6M | 0 | 73.68%33M | -28.00%18M |
| Special income (charges) | -2,833.33%-88M | 40.00%-3M | -500.00%-6M | 0 | 50.00%-5M | -1M | -50.00%-3M | 83.33%-1M | 0 | 87.01%-10M |
| Less:Impairment of capital assets | 0.00%3M | 0.00%3M | 0.00%1M | --0 | 50.00%3M | --1M | 0.00%1M | --1M | --0 | 100.00%2M |
| Less:Other special charges | 325.00%85M | 900.00%20M | ---- | ---- | -75.00%2M | --0 | ---- | ---- | ---- | -89.47%8M |
| Other non-operating income (expenses) | 14.75%70M | 19.61%61M | 155.56%23M | 90.00%19M | -20.31%51M | 14M | 20.00%18M | -35.71%9M | 11.11%10M | 16.36%64M |
| Income before tax | -4.13%1.23B | 40.99%1.28B | 47.40%510M | 469.32%325M | 61.92%910M | 411M | 3,542.86%241M | 44.17%346M | -151.43%-88M | 52.72%562M |
| Income tax | 123.20%404M | -14.62%181M | 302.56%157M | 561.11%83M | 168.35%212M | 135M | 273.33%56M | 225.00%39M | -1,000.00%-18M | 23.44%79M |
| Net income | -25.14%825M | 58.11%1.1B | 15.31%354M | 444.29%241M | 44.31%697M | 275M | 904.35%185M | 34.06%307M | -84.21%-70M | 59.41%483M |
| Net income continuous operations | -25.05%826M | 57.88%1.1B | 14.98%353M | 445.71%242M | 44.51%698M | --276M | 940.91%185M | 34.65%307M | -89.19%-70M | 58.88%483M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -25.14%825M | 58.11%1.1B | 15.31%354M | 444.29%241M | 44.31%697M | 275M | 904.35%185M | 34.06%307M | -84.21%-70M | 59.41%483M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -25.14%825M | 58.11%1.1B | 15.31%354M | 444.29%241M | 44.31%697M | 275M | 904.35%185M | 34.06%307M | -84.21%-70M | 59.41%483M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -25.21%514.99 | 58.73%688.62 | 16.72%220.97 | 453.78%151.31 | 49.17%433.84 | 172.01 | 968.15%115.29 | 37.93%189.31 | -87.34%-42.77 | 63.75%290.83 |
| Diluted earnings per share | -25.21%514.99 | 58.73%688.62 | 16.70%220.9299 | 453.78%151.31 | 49.17%433.84 | 172.01 | 929.20%115.29 | 37.93%189.31 | -87.34%-42.77 | 63.75%290.83 |
| Dividend per share | 133.33%70 | 20 | 0 | 50.00%30 | 30 | 0 | 0 | 0 | 0.00%20 | |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |